[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355289-105":59,"doc-detail-355289-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","ipilimumab-omics-and-head-and-neck-cancersupdate-in-2025","Ipilimumab, -omics, and head and neck cancers—update in 2025","","Immunotherapy with immune checkpoint inhibitors is a key strategy for managing recurrent and metastatic head and neck cancers. The review explains how ipilimumab, an anti-CTLA-4 monoclonal antibody, can be used alone or in combination with nivolumab (anti-PD-1), highlighting that these agents act through distinct T-cell regulatory mechanisms. While some cases show improved efficacy for the dual regimen, overall comparative benefit remains unclear, and microbiome-based biomarkers are discussed amid limited HNC-specific evidence.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ipilimumab-omics-and-head-and-neck-cancersupdate-in-2025/355289/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ipilimumab-omics-and-head-and-neck-cancersupdate-in-2025/355289.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What role does ipilimumab play in head and neck cancer immunotherapy?","Question",{"text":112,"@type":113},"Ipilimumab is an anti-CTLA-4 monoclonal IgG1k antibody used as monotherapy or combined with nivolumab for recurrent and metastatic head and neck cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do ipilimumab and nivolumab differ mechanistically?",{"text":117,"@type":113},"Both regulate T-cell function through different mechanisms of action: CTLA-4 and PD-1 pathway modulation. The review emphasizes that these differences underpin combination strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the overall comparison between ipilimumab and ipilimumab plus nivolumab still unclear?",{"text":121,"@type":113},"Although dual therapy can show better efficacy in some cases, the document states that the overall effect when comparing ipilimumab versus ipilimumab + nivolumab remains unclear.",{"name":123,"@type":110,"acceptedAnswer":124},"What is the significance of the microbiome in response and toxicity?",{"text":125,"@type":113},"The review describes the microbiome as a biomarker influencing responses to immune checkpoint inhibitors and notes microbiome signatures may help prevent ipilimumab-related immune adverse events, while HNC-specific data are limited.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},355289,1790230284,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","TYPE Mini Review  \nPUBLISHED 27 February 2026  \nDOI 10.3389/fimmu.2026.1737862  \nOPEN ACCESS  \nEDITED BY  \nMario Ce´ sar Salinas-Carmona, Universidad Auto´noma de Nuevo Leo´n, Mexico  \nREVIEWED BY  \nVictor Oyervides Juarez,  \nAutonomous University of Nuevo Leo´n, Mexico  \n*CORRESPONDENCE  \nKarolina Kaz´mierczak-Siedlecka  \n [leokadia@gumed.edu.pl](leokadia@gumed.edu.pl)[ ](leokadia@gumed.edu.pl)Leszek Kalinowski  \n [leszek.kalinowski@gumed.edu.pl](leszek.kalinowski@gumed.edu.pl)[ ](leszek.kalinowski@gumed.edu.pl)RECEIVED 02 November 2025 REVISED 16 December 2025 ACCEPTED 23 January 2026 PUBLISHED 27 February 2026  \nCITATION  \nKucharski R, Kosin´ski A, Kalinowski L and Kaz´mierczak-Siedlecka K (2026)  \nIpilimumab, -omics, and head and neck cancers—update in 2025 .  \nFront. Immunol. 17:1737862 .  \ndoi: 10.3389/fimmu.2026.1737862  \nCOPYRIGHT  \n© 2026 Kucharski, Kosin´ ski, Kalinowski and Kaz´mierczak-Siedlecka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIpilimumab, -omics, and head and neck cancers—update in 2025  \nRobert Kucharski 1,2, Adam Kosi ´nski 3,4, Leszek Kalinowski 1,5* and Karolina Ka´zmierczak-Siedlecka 1,2*  \n1Department of Medical Laboratory Diagnostics – Fahrenheit Biobank [BBMRI.pl](BBMRI.pl), Medical University of Gdansk, Gdańsk, Poland, 2 Neodentica Dentistry Center, Gdansk, Poland, 3 Division of Clinical Anatomy, Medical University of Gdansk, Gdańsk, Poland, 4Academy of Applied Medical and Social Sciences, Elblag, Poland, 5 BioTechMed Center, Department of Mechanics of Materials and Structures, Gdansk University of Technology, Gdansk, Poland  \nImmunotherapy employing immune checkpoint inhibitors (ICIs) represents a pivotal approach for the management of recurrent and metastatic head and neck cancers (HNCs) . Ipilimumab is a fully human monoclonal IgG1k antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4), which can be introduced asa monotherapy or dual immunological regimen with nivolumab (antiprogrammed death protein 1, PD-1) . The background of the use of these monoclonal antibodies as combination immunotherapy is strongly associated with their different mechanisms of action. CTLA-4 and PD-1 are able to regulate the function of T cells through different mechanisms. Despite the better efﬁcacy of immunotherapy with ipilimumab + nivolumab in HNCs observed in some cases, the overall effect regarding the comparison of ipilimumab versus ipilimumab + nivolumab is still unclear. The microbiome is one of the biomarkers that affect the response to immunotherapy with ICIs, including ipilimumab. Nevertheless, there is a clear lack of data in this context with regard to HNCs. The beneﬁcial signature of the microbiome contributes to the prevention of the immune-related adverse events caused by ipilimumab. Notably, the incidence of gastrointestinal side effects induced by ICIs is signiﬁcantly increased in the dual regimen with ipilimumab + nivolumab, which affects its recommendation for patients with HNCs  \nKEYWORDS  \nhead and neck cancers, immune checkpoint inhibitors, ipilimumab, microbial metabolites, microbiome, nivolumab  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nKucharski et al. 10.3389/fimmu.2026.1737862  \nGRAPHICAL ABSTRACT  \nHighlights  \n• Ipilimumab, which targets CTLA-4, is utilized for recurrent/metastatic head and neck cancers (HNCs) as amonotherapy or combined with nivolumab. CTLA-4 inhibitors demonstrate comparatively lower activity in HNCs, potentially due to tumor hypoxia impairing Tcell inﬁltration.  \n• Combination therapy (anti-CTLA-4 + anti-PD-1) offers abroader immunologica","cbCaidXy7VcYNQgR","https://ap.wps.com/l/cbCaidXy7VcYNQgR","pdf",9180412,"English","# Introduction\n## Biologic drug categories and delivery routes\n## Rationale for immunotherapy in head and neck cancers\n## Mechanisms of ipilimumab and combination regimens\n## Microbiome and microbiome-derived biomarkers\n## Immune-related adverse events","[{\"question\":\"What role does ipilimumab play in head and neck cancer immunotherapy?\",\"answer\":\"Ipilimumab is an anti-CTLA-4 monoclonal IgG1k antibody used as monotherapy or combined with nivolumab for recurrent and metastatic head and neck cancers.\"},{\"question\":\"How do ipilimumab and nivolumab differ mechanistically?\",\"answer\":\"Both regulate T-cell function through different mechanisms of action: CTLA-4 and PD-1 pathway modulation. The review emphasizes that these differences underpin combination strategies.\"},{\"question\":\"Why is the overall comparison between ipilimumab and ipilimumab plus nivolumab still unclear?\",\"answer\":\"Although dual therapy can show better efficacy in some cases, the document states that the overall effect when comparing ipilimumab versus ipilimumab + nivolumab remains unclear.\"},{\"question\":\"What is the significance of the microbiome in response and toxicity?\",\"answer\":\"The review describes the microbiome as a biomarker influencing responses to immune checkpoint inhibitors and notes microbiome signatures may help prevent ipilimumab-related immune adverse events, while HNC-specific data are limited.\"}]","Ipilimumab, -omics, and head and neck cancers—update in 2025 | PDF",1790117408,15,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd92e67c288e562711ca65e69ee820d3.webp",983,1389,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e20051ae767c9d6728b4b4e4be2869c.webp",982,1388,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5eb072dea1f3b21e9a3fa045c9b829f4.webp",981,1386,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c39abb339324bded12b0fcc0bd58c7f0.webp",980,1385]